Abulafia AS, Shemesh S, Rosenmann L, Berger T, Leader A, Sharf G, Raanani P, Rozovski U (2020) Health-related quality of life in patients with chronic myeloid leukemia treated with first-versus second-generation tyrosine kinase inhibitors Journal of. Clin Med 9(11):1–9

Google Scholar 

Adattini JA, Gross AS, Wong Doo N, McLachlan AJ (2022) Real-world efficacy and safety outcomes of imatinib treatment in patients with chronic myeloid leukemia: an Australian experience. Pharmacol Res Perspect 10:e01005

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ali H, Mohamed Z, Abdullah D (2024) Health-related quality of life in chronic myeloid leukaemia patients receiving long-term therapy with different tyrosine kinase inhibitors in Kurdistan region Georgian Med News: 173–180

Atallah E, Schiffer CA, Radich JP, Weinfurt KP, Zhang MJ, Pinilla-Ibarz J, Kota V, Larson RA, Moore JO, Mauro MJ, Deininger MWN, Thompson JE, Oehler VG, Wadleigh M, Shah NP, Ritchie EK, Silver RT, Cortes J, Lin L, Visotcky A, Baim A, Harrell J, Helton B, Horowitz M, Flynn KE (2021) Assessment of outcomes after stopping tyrosine kinase inhibitors among patients with chronic myeloid leukemia: a nonrandomized clinical trial JAMA. Oncol 7:42–50

Google Scholar 

Aziz Z, Iqbal J, Aaqib M, Akram M, Saeed A (2011) Assessment of quality of life with imatinib mesylate as first-line treatment in chronic phase-chronic myeloid leukemia. Leuk Lymphoma 52:1017–1023

Article  CAS  PubMed  Google Scholar 

Boons C, Timmers L, Janssen J, Westerweel PE, Blijlevens NMA, Smit WM, Bartelink IH, Wilschut JA, Swart EL, Hendrikse NH, Hugtenburg JG (2020) Response and adherence to nilotinib in daily practice (RAND study): an in-depth observational study of chronic myeloid leukemia patients treated with nilotinib. Eur J Clin Pharmacol 76:1213–1226

Article  CAS  PubMed  PubMed Central  Google Scholar 

Borenstein M, Hedges LV, Higgins JPT, Rothstein HR (2009) Introduction to meta-analaysis. John Wiley & Sons

Book  Google Scholar 

Bostan H, Toptas T, Tanrikulu FP, Kut K, Arikan F, Yilmaz F, Atagunduz I, Firatli-Tuglular T (2020) Quality of life and symptom burden with first- and second-generation tyrosine kinase inhibitors in patients with chronic-phase chronic myeloid leukemia. Clin Lymphoma Myeloma Leuk 20:836–842

Article  PubMed  Google Scholar 

Bower H, Bjorkholm M, Dickman PW, Hoglund M, Lambert PC, Andersson TM (2016) Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population. J Clin Oncol 34:2851–2857

Article  CAS  PubMed  Google Scholar 

Caldemeyer L, Dugan M, Edwards J, Akard L (2016) Long-term side effects of tyrosine kinase inhibitors in chronic myeloid leukemia. Curr Hematol Malig Rep 11:71–79

Article  PubMed  Google Scholar 

Cella D, Nowinski CJ, Frankfurt O (2014) The impact of symptom burden on patient quality of life in chronic myeloid leukemia. Oncology 87:133–147

Article  PubMed  Google Scholar 

Chen H, Wen Y, Zeng Y, Lin L, Sun B, Zhu H, He H, Wang X, Zou W, Zheng C, Zheng L, Pang L, Huang J, Zhang Y, Lin H, Zhu W, Wang Q, Zhou X, Liu X, Qu H, Liu Z, Du X, Xu N (2024) Patient versus physician perspective in the management of chronic myeloid leukemia during treatment with tyrosine kinase inhibitors. Oncology and Therapy 12(1):131–145

Article  PubMed  Google Scholar 

Cho HJ, Baek DW, Kim J, Jang YE, Lee Y, Moon JH, Sohn SK (2025) Real-world experience in the management of chronic myeloid leukemia patients focused on tyrosine kinase inhibitors intolerance and health-related quality of life Acta Haematol: 1–14

Cortes JE, Gambacorti-Passerini C, Deininger MW, Mauro MJ, Chuah C, Kim DW, Milojkovic D, le Coutre P, Garcia-Gutierrez V, Crescenzo R, Mamolo C, Reisman A, Hochhaus A, Brummendorf TH, Investigators BS (2019) Patient-reported outcomes in the phase 3 BFORE trial of bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia. J Cancer Res Clin Oncol 145:1589–1599

Article  CAS  PubMed  Google Scholar 

Dahlen T, Edgren G, Ljungman P, Flygt H, Richter J, Olsson-Stromberg U, Wadenvik H, Dreimane A, Myhr-Eriksson K, Zhao J, Sjalander A, Hoglund M, Stenke L (2022) Adverse outcomes in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: Follow-up of patients diagnosed 2002–2017 in a complete coverage and nationwide agnostic register study. Am J Hematol 97:421–430

Article  CAS  PubMed  PubMed Central  Google Scholar 

Efficace F, Baccarani M, Breccia M, Alimena G, Rosti G, Cottone F, Deliliers GL, Barate C, Rossi AR, Fioritoni G, Luciano L, Turri D, Martino B, Di Raimondo F, Dabusti M, Bergamaschi M, Leoni P, Simula MP, Levato L, Ulisciani S, Veneri D, Sica S, Rambaldi A, Vignetti M, Mandelli F (2011) Gimema health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population. Blood 118:4554–4560

Article  CAS  PubMed  Google Scholar 

Efficace F, Baccarani M, Breccia M, Cottone F, Alimena G, Deliliers GL, Barate C, Specchia G, Di Lorenzo R, Luciano L, Turri D, Martino B, Stagno F, Dabusti M, Bergamaschi M, Leoni P, Simula MP, Levato L, Fava C, Veneri D, Sica S, Rambaldi A, Rosti G, Vignetti M, Mandelli F (2013) Chronic fatigue is the most important factor limiting health-related quality of life of chronic myeloid leukemia patients treated with imatinib. Leukemia 27:1511–1519

Article  CAS  PubMed  Google Scholar 

Efficace F, Baccarani M, Breccia M, Saussele S, Abel G, Caocci G, Guilhot F, Cocks K, Naeem A, Sprangers M, Oerlemans S, Chie W, Castagnetti F, Bombaci F, Sharf G, Cardoni A, Noens L, Pallua S, Salvucci M, Nicolatou-Galitis O, Rosti G, Mandelli F (2014) International development of an EORTC questionnaire for assessing health-related quality of life in chronic myeloid leukemia patients: the EORTC QLQ-CML24. Qual Life Res 23:825–836

Article  PubMed  Google Scholar 

Efficace F, Castagnetti F, Martino B, Breccia M, D’Adda M, Angelucci E, Stagno F, Cottone F, Malato A, Trabacchi E, Capalbo SF, Gobbi M, Visani G, Salvucci M, Capodanno I, Tosi P, Tiribelli M, Scortechini AR, Levato L, Maino E, Binotto G, Gugliotta G, Vignetti M, Baccarani M, Rosti G (2018) Health-related quality of life in patients with chronic myeloid leukemia receiving first-line therapy with nilotinib. Cancer 124:2228–2237

Article  CAS  PubMed  Google Scholar 

Efficace F, Iurlo A, Patriarca A, Stagno F, Bee PC, Ector G, Capodanno I, Elena C, Bonifacio M, Blijlevens NMA, Caocci G, Wan C, Abruzzese E, Breccia M, Cottone F, Okumura I, Oerlemans S, Cascavilla N, Albano F, Kota V, Sztankay M, Miggiano MC, Saussele S, Di Renzo N, Sora F, Castagnetti F, Baccarani M, Vignetti M, Rosti G (2021) Validation and reference values of the EORTC QLQ-CML24 questionnaire to assess health-related quality of life in patients with chronic myeloid leukemia. Leuk Lymphoma 62:669–678

Article  CAS  PubMed  Google Scholar 

Efficace F, Rosti G, Aaronson N, Cottone F, Angelucci E, Molica S, Vignetti M, Mandelli F, Baccarani M (2014) Patient- versus physician-reporting of symptoms and health status in chronic myeloid leukemia. Haematologica 99:788–793

Article  PubMed  PubMed Central  Google Scholar 

Efficace F, Stagno F, Iurlo A, Breccia M, Cottone F, Bonifacio M, Abruzzese E, Castagnetti F, Caocci G, Crugnola M, Capodanno I, Martino B, Tiribelli M, Patriarca A, Gozzini A, Pregno P, Saussele S, Cascavilla N, Fozza C, Bergamaschi M, Binotto G, Vignetti M, Rosti G (2020) Health-related quality of life of newly diagnosed chronic myeloid leukemia patients treated with first-line dasatinib versus imatinib therapy. Leukemia 34:488–498

Article  CAS  PubMed  Google Scholar 

Eliasson L, Clifford S, Barber N, Marin D (2011) Exploring chronic myeloid leukemia patients’ reasons for not adhering to the oral anticancer drug imatinib as prescribed. Leuk Res 35:626–630

Article  PubMed  Google Scholar 

Foulon S, Cony-Makhoul P, Guerci-Bresler A, Daban M, Kapso R, Tubert-Bitter P, Bonastre J (2021) Health state utility and quality of life measures in patients with chronic myeloid leukemia in France. Qual Life Res 30:2021–2032

Article  Google Scholar 

Geelen IGP, Thielen N, Janssen J, Hoogendoorn M, Roosma TJA, Willemsen SP, Visser O, Cornelissen JJ, Westerweel PE (2017) Treatment outcome in a population-based, ʽreal-world’ cohort of patients with chronic myeloid leukemia. Haematologica 102:1842–1849

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gibek K (2023) Side effects of treatment with tyrosine kinase inhibitors in patients with chronic myeloid leukaemia and the occurrence of depressive symptoms. Wspolczesna Onkologia 27(4):277–283

Article  CAS  PubMed  Google Scholar 

Gibek K, Sacha T, Cyranka K (2024) Side effects of treatment with tyrosine kinase inhibitors in patients with chronic myeloid leukemia and the occurrence of anxiety symptoms. Psychiatr Pol 58:25–38

Article  PubMed  Google Scholar 

Grant MC, Geoghegan L, Arbyn M, Mohammed Z, McGuinness L, Clarke EL, Wade RG (2020) The prevalence of symptoms in 24,410 adults infected by the novel coronavirus (SARS-CoV-2; COVID-19): A systematic review and meta-analysis of 148 studies from 9 countries. PLoS One 15:e0234765

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hahn EA, Glendenning GA (2003) Quality of life on imatinib. Semin Hematol 40(2):31–36. https://doi.org/10.1053/shem.2003.50039

Article  PubMed  Google Scholar 

Hahn EA, Glendenning GA, Sorensen MV, Hudgens SA, Druker BJ, Guilhot F, Larson RA, O’Brien SG, Dobrez DG, Hensley ML, Cella D, Investigators I (2003) Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: results from the IRIS Study. J Clin Oncol 21:2138–2146

Article  CAS  PubMed